rev: November 18, 1999

HOME (index page)

Return (alphabetical antibody page)

Return  (cytokeratin data page)


CYTOKERATIN   ANTIBODIES  

(anti-Human and others as indicated)

RDI Divison of Fitzgerald Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.


ANTI-CYTOKERATIN  TYPE  19

Mab to Cytokeratin 19

cat#RDI-PRO61010 (same as cat#RDI-CBL178)  $375.00/vial

Clone Determination Ks 19.1

Category Mouse monoclonal

Immunoglobulin Class IgG2a

Purification SpAss-Protein A (recombinant)

Antigen Cytokeratin 19 of Mr 40000; from cultured human MCF-7 cells

Specificity Ks 19.1 represents an excellent marker to discriminate glandular epithelial Ca from those of different origin. No reaction with hepatocellular Ca!

Application Suitable for

· frozen tissue

-paraffin embedded tissue

· immunoblotting (Western)

· cytological Material

Stability/Storage One year after reconstitution when stored at 4°C

Quantity 50 µg (lyoph.) contain 0.5% BSA and 0.09% NaN3



Polypeptide Reacting MR 40 000 polypeptide (cytokeratin 19) of human glandular epithelia

Antigen Recognized in species tested so far:  Human

Reactivities on Cultured                 MCF-7, RT 122, HT-29, Detroit 562, RPMI 2650, SSC-12, HT-29

Cell Lines (tested so far)


Structures and Tissues specifically detcetd:  All tested adeno CA; cholangio CA of liver; renal cell CA; transitional cell of CA of bladder; ovary CA; squamous cell CA of cervix, bronchus and lung (inter-mediate type); mesothelioma; carcinoid tumor of ronchus; breast CA; thymoma


Working Dilution When reconstituted with 1ml distilled water dilute 1:10 with PBS (pH7.2) for immunohistochemistry

Incubation: 1HR RT

References

-Balaton, A.J. et al, Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections. J. Pathol 156, 305-310 (1988)

-Dockhorn-Dworniczak et al:Patterns of expression of cytoskeletal proteins in human thyroid gland and thyroid carcinomas. Differentiation 35, 53-71 (1987)

-Franke, W.W., Moll, R et al:Cell typing of epithelia and carcinomas of the female genital tract using cytoskeletal proteins as markers, Banbury Report 21:Viral Etiology of Cervical Cancer, Cold Spring Harbor Laboratory (NY) 121-148 (1986)

-Karsten U et al, Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion. Eur J Cancer Clin Oncol 21, 733-740 (1985)

-Kasper, M. et al, Histological evaluation of three new monoclonal anti-cytokeratin antibodies 1:Normal tissues Eur J Cancer Clin oncol. 23, 137-147 (1987)

-Lindberg K et al:Suprabasal 40kD keratin (K19) expression as an immunohistochemical marker of premalignancy in oral epithelium. Am J. Pathol 134, 89-98 (1989)

-Moll, R et al:The catalog of human cytokeratins:Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31, 11-24 (1982

-Demirkesen C et al, Epithelial markers and differentiation in adnexal neoplasms of the skin:an immunohistochemical study including individual cytokeratins. J. Cutan Pathol 22:518-535 (1995)

For research use only. Not supplied for use in human diagnostic or therapeutic procedures


RDI Divison of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049

USA

phone (978) 371-6446 or (800) 370-2222

fax     (978) 371-2266

EMAIL:antibodies@fitzgerald-fii.com

RETURN(cytokeratin page)